HOOKIPA Pharma Inc - ESG Rating & Company Profile powered by AI
Check the bottom of the page for potential risks for HOOKIPA Pharma Inc based on industry, location and marketcap. Comprehensive ESG analysis of HOOKIPA Pharma Inc are accessed by registering for free. The webpage is a zero-cost ESG report covering HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.3; made up of an environmental score of 6.0, social score of 5.3 and governance score of 4.6.
5.3
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 886 | Veracyte Inc | 5.4 | High |
| 886 | Xlife Sciences AG | 5.4 | High |
| 912 | HOOKIPA Pharma Inc | 5.3 | High |
| 912 | Acer Therapeutics Inc | 5.3 | High |
| 912 | Alembic Pharmaceuticals Ltd | 5.3 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does HOOKIPA Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes HOOKIPA Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes HOOKIPA Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes HOOKIPA Pharma Inc offer flexible work?
Sign up for free to unlockDoes HOOKIPA Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes HOOKIPA Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes HOOKIPA Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose water use targets?
Sign up for free to unlockDoes HOOKIPA Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid HOOKIPA Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes HOOKIPA Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas HOOKIPA Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes HOOKIPA Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes HOOKIPA Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs HOOKIPA Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes HOOKIPA Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes HOOKIPA Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes HOOKIPA Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for HOOKIPA Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.